A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial - Pujol, J-L; Greillier, L; Audigier-Valette, C (J Thorac Oncol, 2019)
et al.